Nektar Therapeutics (NKTR) Position Lifted by Retirement Systems of Alabama

Retirement Systems of Alabama increased its stake in Nektar Therapeutics (NASDAQ:NKTR) by 23.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 178,088 shares of the biopharmaceutical company’s stock after purchasing an additional 33,562 shares during the period. Retirement Systems of Alabama’s holdings in Nektar Therapeutics were worth $10,856,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Livforsakringsbolaget Skandia Omsesidigt bought a new position in shares of Nektar Therapeutics in the second quarter worth $137,000. Flagship Harbor Advisors LLC bought a new position in shares of Nektar Therapeutics in the second quarter worth $142,000. Raymond James Financial Services Advisors Inc. increased its position in shares of Nektar Therapeutics by 68.7% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 4,290 shares of the biopharmaceutical company’s stock worth $209,000 after purchasing an additional 1,747 shares during the period. Meristem LLP bought a new position in shares of Nektar Therapeutics in the second quarter worth $225,000. Finally, Cambridge Investment Research Advisors Inc. increased its position in shares of Nektar Therapeutics by 27.0% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 4,784 shares of the biopharmaceutical company’s stock worth $234,000 after purchasing an additional 1,018 shares during the period. Institutional investors own 91.94% of the company’s stock.

In other Nektar Therapeutics news, Director Jeffrey Robert Ajer sold 6,750 shares of Nektar Therapeutics stock in a transaction dated Thursday, September 20th. The stock was sold at an average price of $56.76, for a total value of $383,130.00. Following the transaction, the director now owns 15,750 shares in the company, valued at $893,970. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director R Scott Greer sold 10,000 shares of Nektar Therapeutics stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $67.39, for a total value of $673,900.00. Following the completion of the transaction, the director now owns 140,333 shares in the company, valued at approximately $9,457,040.87. The disclosure for this sale can be found here. In the last quarter, insiders sold 96,000 shares of company stock worth $5,825,680. Company insiders own 4.31% of the company’s stock.



Nektar Therapeutics stock opened at $38.68 on Thursday. Nektar Therapeutics has a 12-month low of $22.92 and a 12-month high of $111.36. The company has a current ratio of 19.67, a quick ratio of 19.55 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $6.35 billion, a price-to-earnings ratio of -70.33 and a beta of 2.39.

Nektar Therapeutics (NASDAQ:NKTR) last released its earnings results on Wednesday, August 8th. The biopharmaceutical company reported $5.33 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $5.22 by $0.11. Nektar Therapeutics had a return on equity of 174.70% and a net margin of 65.69%. The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.03 billion. During the same quarter in the previous year, the business posted ($0.39) earnings per share. The business’s revenue for the quarter was up 3043.7% on a year-over-year basis. As a group, equities analysts anticipate that Nektar Therapeutics will post 3.57 earnings per share for the current fiscal year.

A number of research analysts recently commented on NKTR shares. BidaskClub cut Nektar Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, September 18th. Mizuho restated a “buy” rating and issued a $103.00 price target on shares of Nektar Therapeutics in a research report on Thursday, August 9th. Piper Jaffray Companies set a $125.00 price target on Nektar Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, July 25th. Zacks Investment Research cut Nektar Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 10th. Finally, HC Wainwright set a $54.00 price target on Nektar Therapeutics and gave the stock a “hold” rating in a research report on Monday, October 22nd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company’s stock. Nektar Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $82.91.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

Read More: How to Invest in an Index Fund

Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply